HIVNET 023
HIVNET 023. A Phase I/II Study of the Safety and Pharmacokinetics of Nevirapine Given Daily, Twice a Week or Weekly As Prophylaxis in Breastfeeding Infants From Birth to 24 Weeks in Durban, South Africa and Harare, Zimbabwe. Hoosen M. Coovadia, University of Natal, Durban, South Africa
309 views • 14 slides